eMC - trusted, up to date and comprehensive information about medicines

This page has been designed specifically for printing. The full document can be found on the eMC - where you will find trusted, up to date and comprehensive information about medicines.

The eMC provides the latest approved prescribing information (SPCs) and patient information leaflets (PILs) for UK licensed medicines.


Meda Pharmaceuticals

Sky Way House, Parsonage Road, Takeley, Bishop's Stortford, CM22 6PU
Telephone: 0845 460 0000
Fax: 0845 460 0002
Medical Information Direct Line: +44 (0)1748 828 810
Medical Information e-mail: meda@professionalinformation.co.uk
Medical Information Fax: +44 (0)1748 828 801
Out of Hours contact: +44 (0)1748 828 810

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?


Summary of Product Characteristics last updated on the eMC: 03/04/2014

Rhinolast Nasal Spray



1. Name of the medicinal product

Rhinolast® Nasal Spray


2. Qualitative and quantitative composition

Azelastine Hydrochloride 0.1% w/v


3. Pharmaceutical form

Nasal spray


4. Clinical particulars

4.1 Therapeutic indications

For the treatment of both seasonal allergic rhinitis (e.g. hayfever) and perennial allergic rhinitis in patients aged 6 years and over.


4.2 Posology and method of administration

Route of application is topical - nasal mucosa.

Adults

One application (0.14 ml) in each nostril twice daily (0.56 mg of azelastine hydrochloride).

Elderly

There have been no specific studies in the elderly.

Children

For children aged 6 years and older, one application (0.14 ml) in each nostril twice daily (0.56 mg of azelastine hydrochloride).


4.3 Contraindications

Proven allergy against azelastine hydrochloride.


4.4 Special warnings and precautions for use

None.


4.5 Interaction with other medicinal products and other forms of interaction

No specific interactions have been studied.


4.6 Pregnancy and lactation

At high oral doses in animals, 500 times the proposed oral human daily dose, foetal death, growth retardation and an increased incidence of skeletal abnormalities occurred during reproduction toxicity testing. Due to the nasal route of administration and the low dose administered, minimal systemic exposure can be expected. However as with all medicines caution should be exercised with use during pregnancy and lactation.


4.7 Effects on ability to drive and use machines

None.


4.8 Undesirable effects

The following frequencies of undesirable effects were reported:

Commonly (1 - 10 %), a substance-specific bitter taste may be experienced after administration (often due to incorrect method of application, namely tilting the head too far backwards during administration) which, in rare cases, may lead to nausea.

Uncommonly (0.1 - 1 %), a mild, transient irritation of the inflamed nasal mucosa may occur with symptoms such as stinging, itching, sneezing and epistaxis.

In very rare cases (< 0.01 %), hypersensitivity reactions (such as rash, pruritus, urticaria) were reported.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at:

www.mhra.gov.uk/yellowcard.


4.9 Overdose

The results of animal studies show that toxic doses can produce CNS symptoms, e.g. excitation, tremor, convulsions. Should these occur in humans, symptomatic and supportive treatment should be instigated as there is no specific antidote. Gastric lavage is recommended if the overdose is recent.

With the nasal route of administration overdosage reactions are not anticipated.


5. Pharmacological properties

5.1 Pharmacodynamic properties

Azelastine, a phthalazinone derivative of novel structure, is classified as a potent long acting anti-allergic compound with particularly strong H1 antagonist properties.

Data from animal studies show that where high levels of azelastine are achieved both inhibition and release of chemical mediators (e.g. leukotriene, histamine, serotonin) involved in allergic reaction occurs.


5.2 Pharmacokinetic properties

After repeated nasal application (0.14 mg) into each nostril twice daily, the plasma levels of azelastine were about 0.26 ng/ml. The levels of the active metabolite desmethylazelastine were detected at or below the lower limit of quantification (0.12 ng/ml).

After repeated oral administration, the mean Cmax steady state plasma levels were determined giving 3.9 ng/ml for azelastine and 1.86 ng/ml for desmethylazelastine after 2.2 mg b.i.d. azelastine which represents the therapeutic oral dose for the treatment of allergic rhinitis.

Following oral administration azelastine is rapidly absorbed showing an absolute bioavailability of 81%. Food has no influence on absorption. The volume of distribution is high indicating distribution predominantly to the peripheral tissues. The level of protein binding is low (80-95%, a level too low to give concern over drug displacement reactions).

Plasma elimination half lives after a single dose of azelastine are approximately 20 hours for azelastine and about 45 hours for N-desmethylazelastine (a therapeutically active metabolite). Excretion occurs mainly via the faeces. The sustained excretion of small amounts of the dose in the faeces suggest that some enterohepatic circulation may take place.


5.3 Preclinical safety data

Nothing relevant.


6. Pharmaceutical particulars

6.1 List of excipients

Hypromellose, disodium edetate, , citric acid anhydrous, disodium phosphate dodecahydrate, sodium chloride, purified water.


6.2 Incompatibilities

None.


6.3 Shelf life

Three years unopened.


6.4 Special precautions for storage

Do not store below 8°C. Do not refrigerate.


6.5 Nature and contents of container

Polyethylene bottle with polypropylene cap and polyethylene seal containing either 10 ml or 20 ml.

Glass bottle with screw closure and polypropylene seal containing 10 ml, 20 ml or 22 ml.

Glass bottle with pump attached containing 10 ml, 20 ml or 22 ml.

10 ml glass bottle with pump attached, containing 5 ml aqueous solution.

10 ml polyethylene bottle with polypropylene cap and polyethylene seal, containing 5 ml aqueous solution.


6.6 Special precautions for disposal and other handling

For separate bottle and pump

Open the bottle by unscrewing the cap. Place the spray pump nozzle in the bottle and screw the pump onto the bottle. Remove the protective cap. Before first using, squeeze down the collar several times until an even spray emerges. The Rhinolast spray is now ready to use.

For attached pump and bottle

Remove the protective cap. Before first using, squeeze down the collar several times until an even spray emerges. The Rhinolast spray is now ready to use.

Discard product six months after first opening.


7. Marketing authorisation holder

Meda Pharmaceuticals Ltd

Skyway House

Parsonage Road

Takeley

Bishop's Stortford

CM22 6PU

UK


8. Marketing authorisation number(s)

PL 15142/0037


9. Date of first authorisation/renewal of the authorisation

14th August 2009


10. Date of revision of the text

January 2014